First AD

Second AD

The MAINTAIN Trial: Ribociclib in Combination With Endocrine Therapy in Patients With Metastatic Breast Cancer

OncLive News Network®

® video programs provide lively discussions, insights, and expert perspectives on important issues facing today’s cancer care professionals. One variation of the program, titled, 

, comprises live virtual or on-site premium reporting for oncologists as it covers the latest news and information coming out of the largest annual oncology conferences. 

Breast Cancer

ELI-22-OSD1261 - /clinical/colorectal-cancer

 Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

Emerging Therapies in the Management of HR+, HER2- Metastatic Breast Cancer

Laura Huppert, MD, and Yara Abdou, MD, discuss data from the MAINTAIN trial on ribociclib in combination with endocrine therapy in patients with metastatic breast cancer.